Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Apply
Neoantigen Vaccine, DRP-104, Nivolumab, Ipilimumab
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step